Proactive Investors - Run By Investors For Investors

Silence Therapeutics makes clinical trial application for lead drug

Chief executive, Dr David Horn Solomon, said the submission was a “very positive step forward” as it continued preparations for its return to the clinic
Silence Therapeutics makes clinical trial application for lead drug
The company is gearing up to start work in the clinic sometime in the third quarter

Silence Therapeutics PLC (LON:SLN) has made a clinical trial application for its lead candidate, which is being developed to treat iron overload disorders.

SLN124 already has orphan drug designation in Europe, which could shorten its timeline to market while providing the approved product with additional exclusivity.

“Promising candidate medicine”

Silence describes SLN124 as a “promising candidate medicine” for patients with iron overload disorders such as ß -Thalassemia, Myelodysplastic Syndrome and Hereditary Hemochromatosis.

A phase Ib, first-in-human trial is scheduled to start in the third quarter.

Chief executive, Dr David Horn Solomon, said the submission was a “very positive step forward” as Silence continued preparations for its return to the clinic.

“With robust data generated in several preclinical disease models, favourable safety profile and patient-friendly administration, we believe that SLN124 is well positioned against the current standard of care and other medicines in development for the treatment of iron overload disorders.”

View full SLN profile View Profile

Silence Therapeutics PLC Timeline

Related Articles

scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months
Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
Surgery
February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use